导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.60% | 3936/4773 |
| 近一周 | -3.54% | 4289/5462 |
| 近一月 | -9.50% | 4739/5421 |
| 近一季 | -17.23% | 4533/5209 |
| 近半年 | -15.24% | 3976/4920 |
| 近一年 | -13.12% | 3590/4366 |
| 近两年 | 40.01% | 1895/2954 |
| 近三年 | 11.73% | 1705/2253 |
| 成立以来 | 67.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.23% 3087/4961 |
13.96% 1908/5312 |
- - |
- - |
| 2025 | 19.91% 2168/4813 |
-0.60% 2321/3635 |
-1.01% 3089/4076 |
28.97% 1241/4524 |
-5.50% 3567/4813 |
| 2024 | 10.53% 1404/3463 |
-4.74% 1755/2808 |
-4.88% 1578/3014 |
23.60% 380/3129 |
-1.30% 1649/3463 |
| 2023 | -9.91% 1244/2656 |
6.87% 634/2280 |
-5.80% 1537/2385 |
-7.90% 1640/2515 |
-2.83% 541/2655 |
| 2022 | -24.49% 1222/2207 |
-20.73% 1569/1919 |
4.20% 1039/2016 |
-13.23% 862/2113 |
5.35% 470/2208 |
| 2021 | 0.06% 730/1822 |
-6.14% 979/1255 |
18.83% 170/1330 |
-12.67% 1310/1466 |
2.73% 529/1822 |
| 2020 | 55.16% 141/1250 |
3.65% 111/1028 |
28.11% 116/1067 |
6.46% 838/1164 |
9.76% 623/1184 |
| 2019 | - - |
- - |
- - |
6.34% 129/850 |
9.23% 244/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏创业板价值ETF联接A VS. 长安沪深300非周期A(740101) |